Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Daiichi Sankyo has been ordered to pay an 8% royalty ... Insulet is celebrating a jury's verdict that rival South Korean firm EOFlow stole trade secrets relating to its wearable insulin pump ...

South Korea's Samsung Electronics and SK Hynix together control ... home of major drugmakers such as Takeda, Astellas, Daiichi Sankyo and Eisai, which has been expecting strong sales growth in the U.S ...

Sales of Daiichi Sankyo Espha products are no longer recorded ... which we are doing with a collaboration with Alteogen, a Korean company. In terms of Datroway program, we have recently started ...

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking its bid for control of Indian hospital operator Fortis , according to a report ...

Hiroyuki Okuzawa, current COO and incoming CEO of Daiichi Sankyo, talks about the pharmaceutical company's product pipeline, including its cancer treatments, and its global partnerships with ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their second antibody-drug conjugate (ADC) cancer treatment, Datroway, the partners have secured a seventh nod for their ...

Daiichi Sankyo had opposed the open offer made in 2018 after Northern TK Venture had acquired a 31% stake in Fortis. NTK had then filed a lawsuit against Daiichi Sankyo in November 2023.

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster.

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug Administration (FDA) to treat a subset of breast cancer patients. The ...

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...